L-LEUCINE, N-(((2S)-4-((4-METHYL-1H-IMIDAZOL-5-YL)METHYL)-3-OXO-2-(PHENYLMETHYL)-1-PIPERAZINYL)CARBONYL)-
CTCL
Prescient Therapeutics, Ltd.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
61 Active assets in the CTCL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Cyclophosphamide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Bexarotene Case Comprehensive Cancer Center | Phase 4 | BBB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 2 | BBB |
Fludarabine National Cancer Institute (NCI) | Phase 2 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →